AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9466098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lignocaine
Number of subjects: 30
Study 9466098 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lignocaine
Number of subjects: 30
Study 9466098 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 9466098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lignocaine and plain lignocaine
Number of subjects: 30
Study 8192643 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood during initial exposure to spider stimuli
Number of subjects: 48
Study 8192643 — intervention group
Group type: COMPARATOR
Intervention: Elated mood during initial exposure to spider stimuli
Number of subjects: 48
Study 3075434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg orally twice a day)
Number of subjects: 56
Study 3075434 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg orally twice a day)
Number of subjects: 56
Study 31482359 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery (RALS)
Number of subjects: 30
Study 31482359 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery (LS)
Number of subjects: 30
Study 29266177 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure priming
Number of subjects: 90
Study 29266177 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy priming
Number of subjects: 90
Study 29266177 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral priming
Number of subjects: 90
Study 29266177 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 90
Study 29266177 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment security
Number of subjects: 90
Study 29266177 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fear
Number of subjects: 90
Study 28697910 — intervention group
Group type: EXPERIMENTAL
Intervention: Duphaston (20 mg/d)
Number of subjects: 250
Study 28697910 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan (100 mg/d)
Number of subjects: 250
Study 25577227 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (health education and tilt training) plus ORS (with 500 ml of water) - Group I (87 patients)
Number of subjects: 166
Study 25577227 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy - Group II (79 patients)
Number of subjects: 166
Study 23720993 — intervention group
Group type: EXPERIMENTAL
Intervention: OPD-CA axis structure applied in clinical routine procedures
Number of subjects: 42
Study 23720993 — intervention group
Group type: EXPERIMENTAL
Intervention: OPD-CA axis structure
Number of subjects: 42
Study 21721447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipertaz
Number of subjects: 16
Study 21721447 — intervention group
Group type: COMPARATOR
Intervention: Tazocin
Number of subjects: 16
Study 18931845 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonist (VKA) for 30 months
Number of subjects: 34
Study 18931845 — intervention group
Group type: COMPARATOR
Intervention: Discontinue Vitamin K Antagonist (VKA) after 6 months
Number of subjects: 34
Study 16732017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg o.d.)
Number of subjects: 4912
Study 16732017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4912
Study 15353428 — intervention group
Group type: EXPERIMENTAL
Intervention: Faxed physician reminders containing osteoporosis treatment guidelines and patient education
Number of subjects: 102
Study 15353428 — intervention group
Group type: COMPARATOR
Intervention: Usual care and information about falls and home safety
Number of subjects: 102
Study 10755330 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 5 to 30mg once daily
Number of subjects: 0
Study 10755330 — intervention group
Group type: COMPARATOR
Intervention: Extended-release oxybutynin 15mg once daily
Number of subjects: 0
Study 10755330 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 0
Study 9302787 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine provocation test
Number of subjects: 323
Study 9302787 — intervention group
Group type: COMPARATOR
Intervention: PEF variability
Number of subjects: 323
Study 8173166 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate platinum-based therapy
Number of subjects: 8000
Study 8173166 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum in combination
Number of subjects: 8000
Study 8173166 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and cisplatin
Number of subjects: 8000
Study 3669080 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy combined with symptom-specific therapy for sexual dysfunction
Number of subjects: 0
Study 3669080 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and information before sex therapy
Number of subjects: 0
Study 3669080 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 31003664 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga nidra (1-hour sessions, bi-weekly for 8 weeks)
Number of subjects: 40
Study 31003664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 28870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Tripterygium wilfordii Hook F gel
Number of subjects: 168
Study 28870177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 26305240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sex after-school physical activity programs (PA)
Number of subjects: 37
Study 26305240 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group (HL)
Number of subjects: 37
Study 22406907 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP: 35% protein, 40% carbohydrate, 25% fat; 7,000 kJ/day)
Number of subjects: 56
Study 22406907 — intervention group
Group type: COMPARATOR
Intervention: Standard protein diet (SP: 17% protein, 58% carbohydrate, 25% fat; 7,000 kJ/day)
Number of subjects: 56
Study 22406907 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 56
Study 22406907 — intervention group
Group type: COMPARATOR
Intervention: Standard protein diet (SP)
Number of subjects: 56
Study 22406907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 56
Study 21777888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffolds (BVS)
Number of subjects: 161
Study 21777888 — intervention group
Group type: COMPARATOR
Intervention: Metallic Platform Stents (MPS)
Number of subjects: 161
Study 19369231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 317
Study 19369231 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 317
Study 17107493 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise
Number of subjects: 0
Study 17107493 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful irrelevant speech
Number of subjects: 0
Study 17107493 — intervention group
Group type: COMPARATOR
Intervention: Quiet control group
Number of subjects: 0
Study 15363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐I (0.05 mg/kg twice daily by subcutaneous injection)
Number of subjects: 40
Study 15363067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15363067 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐I
Number of subjects: 40
Study 12577434 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiechang Mixture (JCM)
Number of subjects: 60
Study 12577434 — intervention group
Group type: COMPARATOR
Intervention: Fungicidin (Control)
Number of subjects: 60
Study 9700998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (5 or 10 mg once daily)
Number of subjects: 14
Study 9700998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (10 or 20 mg twice daily)
Number of subjects: 14
Study 8090335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 0.3 mg/kg bolus preoperatively, followed by infusion of diltiazem 3 mg/kg/24 h preoperatively and oral diltiazem for 3 months
Number of subjects: 39
Study 8090335 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0.3 mg/kg bolus preoperatively, followed by infusion of placebo 3 mg/kg/24 h preoperatively and oral placebo for 3 months
Number of subjects: 39
Study 8090335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 39
Study 2670608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine baths
Number of subjects: 64
Study 2670608 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated soap baths (Control)
Number of subjects: 64
Study 1071632 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study 1071632 — intervention group
Group type: COMPARATOR
Intervention: Triamterene
Number of subjects: 10
Study 30317345 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed method of pneumoperitonium (Group A)
Number of subjects: 850
Study 30317345 — intervention group
Group type: COMPARATOR
Intervention: Open method of pneumoperitonium (Group B)
Number of subjects: 850
Study 28271903 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective taping
Number of subjects: 18
Study 28271903 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 18
Study 26506778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba injection combined with traditional therapy
Number of subjects: 56
Study 26506778 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (control group)
Number of subjects: 56
Study 24001116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget stepping (MTS) program combined with a multicomponent exercise program
Number of subjects: 264
Study 24001116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study 21263198 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid suppression therapy with thyroxine (T4) 2.5µg/kg/day for two months
Number of subjects: 14
Study 21263198 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 healthy women)
Number of subjects: 14
Study 19055284 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 231
Study 19055284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drug (Wuzi Yanzong Pill)
Number of subjects: 231
Study 19055284 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 231
Study 16224108 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation for 24 hours (n = 79)
Number of subjects: 162
Study 16224108 — intervention group
Group type: COMPARATOR
Intervention: Conventional management with oxygen therapy (control group, n = 83)
Number of subjects: 162
Study 16224108 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation in hypercapnic patients
Number of subjects: 162
Study 16224108 — intervention group
Group type: COMPARATOR
Intervention: Conventional management in hypercapnic patients
Number of subjects: 162
Study 12952258 — intervention group
Group type: EXPERIMENTAL
Intervention: AKITA system (inhalation device)
Number of subjects: 6
Study 12952258 — intervention group
Group type: EXPERIMENTAL
Intervention: PARI‐LC Star (inhalation device)
Number of subjects: 6
Study 12952258 — intervention group
Group type: EXPERIMENTAL
Intervention: HaloLite (inhalation device)
Number of subjects: 6
Study 12952258 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin (5% solution)
Number of subjects: 6
Study 11071407 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially expanding 10‐mm trocar
Number of subjects: 54
Study 11071407 — intervention group
Group type: COMPARATOR
Intervention: Conventional 10‐mm metal trocar
Number of subjects: 54
Study 9118653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 8
Study 9118653 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine plus norepinephrine
Number of subjects: 8
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular stimulation with hMG in insemination cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular stimulation with CC in insemination cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular stimulation with hMG in intercourse cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular stimulation with CC in intercourse cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Insemination cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse cycles
Number of subjects: 148
Study 8458457 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI and direct intraperitoneal insemination
Number of subjects: 148
Study 3702643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple vitamin, multiple mineral supplement containing 18 mg iron for 8 months
Number of subjects: 19
Study 3702643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30043913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D level (25(OH) vitamin D)
Number of subjects: 50
Study 30043913 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 50
Study 30043913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D level cut-off
Number of subjects: 50
Study 25932920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0
Study 25932920 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0
Study 25932920 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 0
Study 25932920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24906584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% atropine eye drops plus auricular acupoint stimulation (0.125A + ACU group)
Number of subjects: 110
Study 24906584 — intervention group
Group type: COMPARATOR
Intervention: 0.125% atropine alone (0.125A group)
Number of subjects: 110
Study 24260145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for social anxiety disorder
Number of subjects: 314
Study 20237361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extracorporeal shockwave therapy
Number of subjects: 60
Study 20237361 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroid injection
Number of subjects: 60
Study 19009658 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g n‐3 polyunsaturated fatty acids (PUFA) from seal oils, three times a day, along with a recommended diet
Number of subjects: 144
Study 19009658 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 g, three times a day, along with a recommended diet
Number of subjects: 144
Study 16456383 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 22
Study 12730769 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate 2 g daily
Number of subjects: 9196
Study 12730769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9196
Study 10969106 — intervention group
Group type: EXPERIMENTAL
Intervention: Study fortifier (SF)
Number of subjects: 144
Study 10969106 — intervention group
Group type: COMPARATOR
Intervention: Commercial fortifier (CF)
Number of subjects: 144
Study 8838764 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid endothelin-1 (ET-1) levels measured in aneuploid pregnancies
Number of subjects: 53
Study 8838764 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid endothelin-1 (ET-1) levels measured in euploid pregnancies
Number of subjects: 53
Study 1332435 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0
Study 1332435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3523938 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylstilbestrol (DES) or bilateral orchiectomy
Number of subjects: 319
Study 3523938 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide plus 5‐fluorouracil plus DES
Number of subjects: 319
Study 3523938 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Emcyt)
Number of subjects: 319
Study 29902226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic modulation during incidental learning
Number of subjects: 0
Study 29902226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25796103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (n = 14) received 1.7 g protein/kg/day during admission and a daily protein supplement (18.8 g protein) and resistance training 3 times per week for 12 weeks after discharge
Number of subjects: 29
Study 25796103 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 15)
Number of subjects: 29
Study 23857507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir + telbivudine (group 1)
Number of subjects: 0
Study 23857507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir followed by adefovir + telbivudine (group 2)
Number of subjects: 0
Study 23857507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine + adefovir followed by adefovir + telbivudine (group 3)
Number of subjects: 0
Study 23857507 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 0
Study 22784897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-midvastus approach (MMV group)
Number of subjects: 60
Study 22784897 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach (MPP group)
Number of subjects: 60
Study 20575712 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard gel
Number of subjects: 0
Study 20575712 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 18177949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intervention, specific dosage and duration not available
Number of subjects: 0
Study 18177949 — intervention group
Group type: COMPARATOR
Intervention: Placebo control, specific details not available
Number of subjects: 0
Study 16827627 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping improvement group intervention (12 sessions delivered via teleconference)
Number of subjects: 90
Study 16827627 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 90
Study 16827627 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping improvement group intervention
Number of subjects: 90
Study 12793558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (group A)
Number of subjects: 207
Study 12793558 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (group B)
Number of subjects: 207
Study 12793558 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall headache reporting
Number of subjects: 207
Study 9917782 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia plus intracameral 1% preservative-free lidocaine
Number of subjects: 68
Study 9917782 — intervention group
Group type: COMPARATOR
Intervention: Intracameral balanced salt solution
Number of subjects: 68
Study 7571782 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 15000
Study 7571782 — intervention group
Group type: COMPARATOR
Intervention: Alternative devices (excimer laser, rotablator, directional atherectomy, stents)
Number of subjects: 15000
Study 2182208 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine treatment (100 mg bolus followed by 2 mg.kg-1 for at least the first 24 hours)
Number of subjects: 83
Study 2182208 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 83
Study 99690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 10
Study 99690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (open trial)
Number of subjects: 10
Study 30621733 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-lateral position
Number of subjects: 135
Study 30621733 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-lateral position
Number of subjects: 135
Study 30621733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 135
Study 30621733 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 135
Study 27912104 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured practice group (SPG) with skill progression
Number of subjects: 20
Study 27912104 — intervention group
Group type: COMPARATOR
Intervention: Unstructured practice group (UPG) without skill progression
Number of subjects: 20
Study 24687247 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Essential Oils (M-EO)
Number of subjects: 15
Study 24687247 — intervention group
Group type: COMPARATOR
Intervention: 0.2 % Chlorhexidine (M-0.2 % chlorhexidine)
Number of subjects: 15
Study 24687247 — intervention group
Group type: COMPARATOR
Intervention: M-WATER
Number of subjects: 15
Study 23880971 — intervention group
Group type: EXPERIMENTAL
Intervention: OPN-305
Number of subjects: 41
Study 23880971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22084333 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-Hz WBV therapy
Number of subjects: 202
Study 22084333 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-Hz WBV therapy
Number of subjects: 202
Study 22084333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WBV therapy)
Number of subjects: 202
Study 19501587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 140
Study 19501587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 17016233 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEK2 SNP rs2017309 A allele presence
Number of subjects: 213
Study 17016233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy and radiotherapy
Number of subjects: 213
Study 15799931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher drug-eluting stents
Number of subjects: 200
Study 15799931 — intervention group
Group type: COMPARATOR
Intervention: BITA grafting
Number of subjects: 200